HER2+ Metastatic Breast Cancer (MBC) Active Not Recruiting Phase 3 Trials for Lapatinib (DB01259)

DBCOND0062591 (HER2+ Metastatic Breast Cancer (MBC))Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01808573A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingTreatment